Stockscreener 앱 받기
1.49
1.97%
-0.03
시장 영업 전:
1.52
0.03
+2.01%
전일 마감가:
$1.52
열려 있는:
$1.49
하루 거래량:
53,667
Relative Volume:
0.28
시가총액:
$15.62M
수익:
$1.85M
순이익/손실:
$-5.26M
주가수익비율:
-1.5764
EPS:
-0.9452
순현금흐름:
-
1주 성능:
-3.86%
1개월 성능:
-18.58%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$1.48
$1.57
1주일 범위
$1.45
$1.67
52주 변동 폭
$1.45
$14.09
20 20 Biolabs Inc Stock (AIDX) Company Profile
Compare AIDX vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AIDX
20 20 Biolabs Inc
|
1.49 | 15.62M | 1.85M | -5.26M | 0 | -0.9452 |
ABT
Abbott Laboratories
|
87.17 | 151.83B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
295.25 | 113.08B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
77.79 | 99.87B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
55.98 | 83.21B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.91 | 47.80B | 6.30B | 1.07B | 1.34B | 1.8406 |
20 20 Biolabs Inc 주식(AIDX)의 최신 뉴스
20/20 BioLabs licenses kidney disease prediction technology from ROKIT Healthcare - MSN
20/20 Biolabs Inc. (AIDX) Earnings Yield (TTM) - Zacks Investment Research
AIDX SEC Filings20/20 Biolabs Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Is 20/20 Biolabs (AIDX) stock a strong buy |Bond Issuance - Newser
20/20 Biolabs Inc. (AIDX) - Zacks Investment Research
20/20 Biolabs Inc. (AIDX) Gross Margin (TTM) - Zacks Investment Research
20/20 BioLabs blood test platform targeting early detection of hard-to-screen Cancers - Proactive financial news
20/20 Biolabs (NASDAQ: AIDX) cuts warrant price, registers 15.16M shares - Stock Titan
Warrant strike cut to $2.25 as 20/20 Biolabs (NASDAQ: AIDX) registers 10.1M shares - Stock Titan
Streeterville warrant repricing at 20/20 Biolabs (NASDAQ: AIDX) drops strike - Stock Titan
AIDX Price Today: 20/20 Biolabs, Inc. Stock Price, Quote & Chart - MEXC
AIDX (20/20 Biolabs) highlights rising clinical test adoption as core growth driver in latest quarterly earnings.Community Trade Ideas - Newser
How to Value 20/20 Biolabs (AIDX) Stock (Technical Strength) 2026-04-22Community Driven Stock Picks - Cổng thông tin điện tử Tỉnh Sơn La
20/20 BIOLABS INC Company Profile & Introduction - Moomoo
AIDX | 20/20 Biolabs, Inc. Common Insider Trading - Quiver Quantitative
20/20 Biolabs (AIDX) Stock Chart and Price History 2026 - MarketBeat
BIO-key International, 20/20 Biolabs, Society Pass, and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
20/20 Biolabs (NASDAQ: AIDX) resale prospectus: 10.105M shares may be sold - Stock Titan
15.16M shares available for resale as 20/20 Biolabs (NASDAQ: AIDX) direct listing - Stock Titan
[EFFECT] 20/20 Biolabs, Inc. SEC Filing - Stock Titan
AIDX: 20/20 Biolabs Inc.Comparison to Industry - Zacks Investment Research
Dividend History20/20 Biolabs Inc. (AIDX) - Zacks Investment Research
20/20 BioLabs Selected by Evexia Diagnostics to Offer OneTest™ for Cancer Through Evexia Platform - Sahm
Multi-Cancer Early Detection Test Added to Evexia Diagnostics Platform - Clinical Lab Products
Cancer test reaches 40,000 practitioners through Evexia platform - Stock Titan
20/20 BioLabs’ Multi-Cancer Early Detection Test Now Available to Evexia Diagnostics' 40,000+ U.S. Practitioners - The Desert Sun
20/20 Biolabs (AIDX) CFO receives 100,000-share stock option grant - Stock Titan
COO of 20/20 Biolabs (AIDX) granted 150,000 options at $1.88 - Stock Titan
Resale of 10.1M 20/20 Biolabs (Nasdaq: AIDX) shares amid losses - Stock Titan
20/20 Biolabs (NASDAQ: AIDX) 15.16M-share resale registration - Stock Titan
AIDX : 20/20 Biolabs Inc. Key Company Metrics & Non-finance Metrics - Zacks Investment Research
20/20 Biolabs, Inc. (AIDX) stock price, news, quote and history - Yahoo Finance Singapore
20/20 BioLabs (AIDX) Reports 17% Revenue Growth in 2025 and Eyes Significant Expansion in 2026 with AI-Powered Cancer Detection Blood Tests - Minichart
20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress - The Manila Times
All News for AIDX : 20/20 Biolabs Inc. - Zacks Investment Research
20/20 BioLabs (AIDX) grows 2025 revenue 17% and narrows annual net loss - Stock Titan
20/20 Biolabs 10-K: Revenues $2.05M, Net Loss $(3.74)M - TradingView — Track All Markets
20/20 Biolabs (NASDAQ: AIDX) outlines AI blood tests, longevity and growth - Stock Titan
20/20 Biolabs, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Maryland funds firefighter cancer tests as 20/20 lifts margins - Stock Titan
AIDX | 20/20 Biolabs, Inc. Common Institutional Ownership - Quiver Quantitative
AIDX | 20/20 Biolabs, Inc. Common Stock Data, Price & News - Quiver Quantitative
20/20 Biolabs Unchanged on News - Baystreet.ca
20/20 BioLabs announces grants for Maryland fire departments to procure OneTest - TipRanks
Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs’ OneTest ™ Multi-Cancer Early Detection Blood Test - The Manila Times
Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs' OneTest Multi-Cancer Early Detection Blood Test - Bitget
20/20 BioLabs licenses kidney disease prediction technology By Investing.com - Investing.com India
20/20 BioLabs Secure U.S. License For Advanced CKD Prediction Technology - RTTNews
20 20 Biolabs Inc (AIDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.41%
0.93%
자본화:
|
볼륨(24시간):